McKesson Corporation (MCK) continues to emerge as a resilient company in the bio-tech market. Notable finance authorities such as
Jim Cramer and
Cliff Asness have recommended the stock as a strong addition to any investment portfolio. McKesson's
high institutional backing of 88% signals strong market confidence. Despite occasional underperformance against competitors, it remains a strong value stock in the long-term. McKesson has been surpassing
earnings guidance expectations, making it attractive to investors. Driven by its focus on
oncology, McKesson has demonstrated
continuous growth, even amid revenue miss situations. However, there's been a
sale of shares from both insiders and institutions, and
underperformance when compared to market expectations. Finally,
McKesson has raised its full-year EPS guidance after Q2 earnings beat, which should be of interest to investors.
Mckesson Corporation MCK News Analytics from Tue, 07 May 2024 07:00:00 GMT to Sat, 21 Dec 2024 10:29:04 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -2
